Disease-specific factors associated with cardiovascular events in patients with Takayasu arteritis

Table 3 Risk of cardiovascular disease according to TAK disease-specific factors

	Univariable analysis		Multivariable analysis^a
	Unadjusted HR (95% CI)	P value	Adjusted HR (95% CI)	P value
BMI	1.031 (0.926–1.146)	0.579	0.905 (0.796–1.029)	0.129
Anemia	0.880 (0.468–1.654)	0.691	0.924 (0.464–1.838)	0.821
ESR	1.001 (0.991–1.011)	0.878	0.996 (0.985–1.008)	0.551
CRP	0.995 (0.986–1.005)	0.326	0.993 (0.982–1.003)	0.183
Vascular involvement type
Types other than V	1.000 (reference)		1.000 (reference)
Type V	2.741 (1.443–5.205)	0.002	2.852 (1.474–5.518)	0.002
Pulmonary artery involvement	1.011 (0.311–3.288)	0.985	0.717 (0.193–2.655)	0.618
Aortic regurgitation	1.341 (0.703–2.558)	0.373	1.024 (0.505–2.077)	0.947
Use of glucocorticoids
None-to-low dose	1.000 (reference)		1.000 (reference)
Medium-to-high dose	0.780 (0.414–1.471)	0.443	1.030 (0.523–2.030)	0.932
Use of MTX	0.474 (0.253–0.887)	0.020	0.515 (0.268–0.993)	0.047
Use of AZA	0.592 (0.231–1.513)	0.273	0.768 (0.278–2.122)	0.611
Use of aspirin	1.763 (0.880–3.532)	0.110	1.426 (0.695–2.925)	0.333
Use of statins	1.220 (0.640–2.327)	0.546	0.789 (0.391–1.592)	0.508

TAK Takayasu arteritis, HR hazard ratio, CI confidence interval, BMI body mass index, ESR erythrocyte sedimentation rate, CRP C-reactive protein, MTX methotrexate, AZA azathioprine
^aAdjusted for traditional cardiovascular risk factors (age, sex, systolic BP, use of antihypertensive drugs, total cholesterol, HDL cholesterol, diabetes mellitus, and smoking status)

ISSN: 1478-6362